Gilotrif Approval History
- FDA approved: Yes (First approved July 12th, 2013)
- Brand name: Gilotrif
- Generic name: afatinib
- Company: Boehringer Ingelheim Pharmaceuticals, Inc.
- Treatment for: Non-Small Cell Lung Cancer
Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).
FDA Approval History for Gilotrif
|Jul 12, 2013||FDA Approves Gilotrif for Late Stage Non-Small Cell Lung Cancer|
|Jan 15, 2013||U.S. FDA Grants Priority Review to Boehringer Ingelheim's Afatinib NDA for EGFR Mutation-Positive Advanced NSCLC|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.